Abstract
Background
Moraxella catarrhalis (M. catarrhalis) is an important bacterial pathogen. However, its antibiotic susceptibility patterns in different areas are difficult to compare because of the use of different methods and judgement criteria. This study aimed to determine antimicrobial susceptibility and β-lactamase activity characteristics of M. catarrhalis isolates collected from two county hospitals in China, and to express the results with reference to three commonly used judgement criteria.
Results
Nasopharyngeal swabs were obtained from child inpatients with respiratory tract infections at the People’s Hospital of Zhongjiang County and Youyang County from January to December 2015. M. catarrhalis strains were isolated and identified from the swabs, and susceptibility against 11 antimicrobials was determined using the E-test method or disc diffusion. Test results were interpreted with reference to the standards of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Clinical and Laboratory Standards Institute (CLSI), and the British Society for Antimicrobial Chemotherapy (BSAC). Detection of β-lactamase activity was determined by the chromogenic cephalosporin nitrocefin. M. catarrhalis yield rates were 7.12 and 9.58% (Zhongjiang County, 77/1082 cases; Youyang County, 101/1054 cases, respectively). All isolates were susceptible to amoxicillin–clavulanic acid. The susceptibility rate to meropenem was 100% according to EUCAST; no breakpoints were listed in CLSI or BSAC. The non-susceptibility rate to sulfamethoxazole-trimethoprim differed significantly between the two hospitals regardless of the judgemnet criteria used, with isolates from Zhongjiang showing higher susceptibility to those from Youyang (Fisher’s exact test, P < 0.05). According to CLSI, the total non-susceptibility rate to erythromycin was 70.8% (Zhongjiang County, 79.2%; Youyang County, 64.3%), and the rate reached 92.1% (Zhongjiang County, 90.9%; Youyang County, 93.1%) on the basis of EUCAST or BSAC. The total positive rate of β-lactamase was 99.4% (177/178 cases) (Zhongjiang County, 100%, 77/77 cases; Youyang County, 99.0%, 100/101 cases).
Conclusions
Ninety nine percent of M. catarrhalis isolates produce β-lactamase. The isolates showed poor susceptibility to ampicillin and erythromycin, and high susceptibility to the third- and fourth-generation cephalosporins and amoxicillin–clavulanic. Significant discrepancies between different antimicrobial susceptibility judgemnet criteria were noted.
Keywords: Moraxella catarrhalis, Antibiotic resistance, β-Lactamase, Children
Background
Moraxella catarrhalis (M. catarrhalis), also known as Micrococcus catarrhalis, Neisseria catarrhalis, and Branhamella catarrhalis is a gram-negative, aerobic, oxidase-positive diplococcus. It is a commensal species that is exclusively a human pathogen of the upper respiratory tract. However, it is now recognized as causative of otitis media in children and acute exacerbations of chronic obstructive pulmonary disease in adults [1, 2]. M. catarrhalis can also cause endocarditis, sepsis and meningitis, though these occur more rarely [1].
Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality in children worldwide, and M. catarrhalis is the third most common causative pathogenic bacteria of CAP, following Streptococcus pneumoniae and Haemophilus influenzae [3]. The importance of M. catarrhalis in CAP infection is also increasing with the introduction of the pneumococcal conjugate vaccine and Haemophilus influenzae type b vaccine.
The first β-lactamase positive M. catarrhalis isolate was reported in 1977 in Sweden [4]. Since then, β-lactamase production has been reported from various countries with different frequencies, which mostly exceed 90.0% [3, 5–7], revealing the poor antibiotic susceptibility pattern of the isolate. Three antimicrobial resistance judgemnet criteria can be used to analyze the antibiotic susceptibility pattern of M. catarrhalis strains: the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Clinical and Laboratory Standards Institute (CLSI) [8], and the British Society for Antimicrobial Chemotherapy (BSAC) [9]; CLSI is most commonly used in China. Because of the lack of a unified testing method and judgemnet criteria for antibiotic resistance of M. catarrhalis, data from different areas show significant differences [10, 11]. Moreover, susceptibility testing of M. catarrhalis is not routinely performed in most diagnostic laboratories, and many resistance data derive from large cities, with few studies conducted in more rural areas. Therefore, the aim of this study was to determine the level of β-lactamase production and antibiotic resistance patterns of M. catarrhalis isolates collected from two county hospitals in China.
Methods
Study population
Nasopharyngeal swabs were collected from child inpatients with respiratory tract infections at the People’s Hospitals of Zhongjiang County and Youyang County, located in western China, from January to December 2015. Children meeting the following criteria were included: (1) aged between 1 month and 14 years; (2) having an infection for fewer than 3 days; (3) having a fever and cough; and (4) with permission from a parent and/or legal guardian. Children with factors potentially affecting the acquisition of nasopharyngeal swab specimens, such as repeated tic, and coagulation disorders, were excluded.
A total of 1082 children were included from Zhongjiang County, of whom 642 were male and 440 were female; a total of 1054 were included from Youyang County, of whom 679 were male and 375 were female. Chocolate agar and blood agar were used to culture the specimens, which were incubated for 24 h at 37 °C. Bacterial growth was identified by the examination of colony morphology, gram staining, and microscopic analysis. Additional identification tests were the oxidase test, catalase test, carbohydrate fermentation test, DNAse test, and nitrate reduction test.
A parent and/or legal guardian of each participant signed a written informed consent document before enrollment and before any study procedure was performed. This study was approved by the Ethics Committee of the two hospitals (Ethics Committee of People’s Hospital of Zhongjiang County, and Ethics Committee of People’s Hospital of Chongqing Youyang County). No ethical problems were encountered in this study.
Antimicrobial susceptibility and β-lactamase testing
The minimum inhibitory concentrations (MICs) of all isolates were determined against ampicillin, amoxicillin–clavulanic acid, cefuroxime, ceftazidime, cefepime, ciprofloxacin, erythromycin, and meropenem using E-test strips (AB Biodisk, Solna, Sweden), and their susceptibility to sulfamethoxazole–trimethoprim, chloramphenicol, and tetracycline was assessed with disc diffusion tests (Oxoid, Basingstoke, England). The results were interpreted with reference to the standards of EUCAST(http://www.eucast.org/clinical_breakpoints/), CLSI [8], and BSAC [9], and breakpoints are listed in Table 1. β-lactamase activity was determined by the chromogenic cephalosporin nitrocefin (BR66A; Oxoid). Streptococcus pneumoniae ATCC49619 was used as the quality control strain in susceptibility tests.
Table 1.
Antibiotic breakpoints for M. catarrhalis strains in EUCAST, CLSI and BSAC
| Antibiotics* | MICa/D-zoneb | EUCASTc | CLSId | BSACe | |||||
|---|---|---|---|---|---|---|---|---|---|
| S | R | S | I | R | S | I | R | ||
| AMP | MIC(mg/L) | -# | -# | -# | -# | -# | ≤1 | – | > 1 |
| AMC | MIC(mg/L) | ≤1 | >1 | ≤4 | – | ≥8 | ≤1 | – | > 1 |
| CXM | MIC(mg/L) | ≤4 | >8 | ≤4 | 8 | ≥16 | ≤1 | 2 | > 2 |
| CAZ | MIC(mg/L) | -# | -# | ≤2 | -# | -# | -# | -# | -# |
| FEP | MIC(mg/L) | ≤4 | >4 | -# | -# | -# | -# | -# | -# |
| CIP | MIC(mg/L) | ≤0.5 | >0.5 | ≤1 | -# | -# | ≤0.5 | – | > 0.5 |
| ERY | MIC(mg/L) | ≤0.25 | >0.5 | ≤0.5 | 1–4 | ≥8 | ≤0.25 | 0.5 | > 0.5 |
| MEM | MIC(mg/L) | ≤2 | >2 | -# | -# | -# | -# | -# | -# |
| TCY | D-zone(mm) | ≥28 | <25 | ≥29 | 25–28 | ≤24 | ≥22 | – | ≤21 |
| CHL | D-zone(mm) | ≥30 | <30 | -# | -# | -# | -# | -# | -# |
| SXT | D-zone(mm) | ≥18 | <15 | ≥13 | 11–12 | ≤10 | ≥12 | – | ≤11 |
aMIC minimum inhibitory concentration, bD-zone diameter of inhibition zone, cEUCAST, European Committee on Antimicrobial Susceptibility Testing, dCLSI Clinical and Laboratory Standards Institute, eBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints listed in the according criterion
Statistical analysis
Antimicrobial resistance data were analyzed with WHONET 5.6 software as recommended by the World Health Organization. Statistical analyses were performed using SPSS software 17.0 (SPSS, Chicago, IL). The χ2 test and Fisher’s exact test were used for significant comparisons between groups. P values < 0.05 were deemed to indicate statistical significance.
Results
A total of 77 and 101 M. catarrhalis isolates were separately detected from Zhongjiang and Youyang counties, respectively, with yield rates of 7.12% (77/1082 cases) and 9.58% (101/1054 cases). There was no significant difference in the yield rate between boys (6.7%; 43/642 cases) and girls (7.7%; 34/440 cases) in Zhongjiang County (χ2 = 0.419, P = 0.518), or in Youyang County (9.0%; 61/679 cases and 10.7%; 40/375 cases, respectively, χ2 = 0.790, P = 0.374).
Table 2 shows the susceptibility and the MICs of the isolates against 11 antibiotics. All isolates were susceptible to amoxicillin–clavulanic acid. The susceptibility rate to meropenem was 100% according to EUCAST; no equivalent breakpoints are listed in CLSI or BSAC. Regardless of the criteria used, the strains showed poor susceptibility to erythromycin. According to CLSI, the total non-susceptibility rate to erythromycin was 70.8% (Zhongjiang County, 79.2%; Youyang County, 64.3%), and this reached 92.1% (Zhongjiang County, 90.9%; Youyang County, 93.1%) according to EUCAST or BSAC. The MICs of 21.9% (39/178 cases) of the isolates were > 256 mg/L. Non-susceptibility to sulfamethoxazole-trimethoprim was significantly different between the two hospitals, regardless of the judgemnet criteria used, with isolates from Zhongjiang more susceptible than those from Youyang (Fisher’s exact test, P < 0.05). The total positive rate of β-lactamase was 99.4% (177/178 cases): 99.0% (100/101 cases) in Youyang County and 100% (77/77 cases) in Zhongjiang County.
Table 2.
Susceptibility of the Moraxella catarrhalis isolates in Youyang, Zhongjiang and total profiles according to EUCAST, CLSI and BSAC
| Antibiotics* | Youyang | Zhongjiang | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I% | R% | MIC50 | MIC90 | MIC Range | I% | R% | MIC50 | MIC90 | MIC Range | I% | R% | MIC50 | MIC90 | MIC Range | ||
| EUCASTa | AMP | – | – | 2 | 4 | 0.016~ 16 | – | – | 2 | 6 | 0.032~ 12 | – | – | 2 | 6 | 0.032–12 |
| AMC | – | 0 | 0.19 | 0.38 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016–0.38 | |
| CXM | 8.9 | 0 | 2 | 4 | 0.023~ 8 | 18.2 | 1.3 | 3 | 6 | 0.047~ 16 | 12.9 | 0.6 | 3 | 6 | 0.047–16 | |
| CAZ | – | – | 0.125 | 0.38 | 0.023~ 2 | – | – | 0.094 | 0.38 | 0.032~ 1 | – | – | 0.094 | 0.38 | 0.032–1 | |
| FEP | – | 4.0 | 1.5 | 4 | 0.064~ 6 | – | 1.3 | 1.5 | 4 | 0.19~ 6 | – | 2.8 | 1.5 | 4 | 0.19–6 | |
| CIP | – | 2.0 | 0.047 | 0.19 | 0.016~ 1 | – | 5.2 | 0.047 | 0.094 | 0.016~ 1 | – | 3.4 | 0.047 | 0.094 | 0.016–1 | |
| ERY | 28.7 | 64.4 | 0.75 | > 256 | 0.047~ > 256 | 11.7 | 79.2 | 2 | > 256 | 0.19~ > 256 | 21.3 | 70.8 | 2 | 256 | 0.19- > 256 | |
| MEM | – | 0 | 0.006 | 0.008 | 0.003~ 0.38 | – | 0 | 0.006 | 0.008 | 0.003~ 0.023 | – | 0 | 0.006 | 0.008 | 0.003–0.38 | |
| TCY | 3.0 | 5.9 | 0 | 3.9 | 1.7 | 5.1 | ||||||||||
| CHL | – | 4.0 | – | 3.9 | – | 3.9 | ||||||||||
| SXT | 9.9 | 30.7 | 7.8 | 3.9 | 9.0 | 19.1 | ||||||||||
| CLSIb | AMC | – | 0 | 0.19 | 0.38 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016–0.38 |
| CXM | 8.9 | 0 | 2 | 4 | 0.023~ 8 | 18.2 | 1.3 | 3 | 6 | 0.047~ 16 | 12.9 | 0.6 | 3 | 6 | 0.047–16 | |
| CAZ | -# | -# | 0.125 | 0.38 | 0.023~ 2 | -# | -# | 0.094 | 0.38 | 0.032~ 1 | -# | -# | 0.094 | 0.38 | 0.032–1 | |
| CIP | -# | -# | 0.047 | 0.19 | 0.016~ 1 | -# | -# | 0.047 | 0.094 | 0.016~ 1 | -# | -# | 0.047 | 0.094 | 0.016–1 | |
| ERY | 48.5 | 15.8 | 0.75 | > 256 | 0.047~ > 256 | 44.1 | 35.1 | 2 | > 256 | 0.19~ > 256 | 47.8 | 23.0 | 2 | > 256 | 0.19- > 256 | |
| TCY | 20.8 | 5.9 | 3.9 | 3.9 | 13.5 | 5.1 | ||||||||||
| SXT | 6.9 | 16.8 | 0 | 1.3 | 3.9 | 10.1 | ||||||||||
| BSACc | AMP | – | 68.3 | 2 | 4 | 0.016~ 16 | – | 81.8 | 2 | 6 | 0.032~ 12 | – | 74.2 | 2 | 6 | 0.032–12 |
| CXM | 45.5 | 49.5 | 2 | 4 | 0.023~ 8 | 44.2 | 53.2 | 3 | 6 | 0.047~ 16 | 44.9 | 51.1 | 3 | 6 | 0.047–16 | |
| TCY | – | 5.9 | – | 3.9 | – | 5.1 | ||||||||||
| SXT | – | 19.8 | – | 1.3 | – | 11.8 | ||||||||||
aEUCAST European Committee on Antimicrobial Susceptibility Testing, bCLSI Clinical and Laboratory Standards Institute, cBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints were listed in the according criterion, but the other “-“s mean no data
Discussion
Research into the antibiotic resistance of M. catarrhalis strains is limited, and the use of different judgemnet criteria makes it difficult to compare data between studies.Three criteria are commonly used in antimicrobial susceptibility testing for M. catarrhalis: EUCAST, CLSI, and BSAC. Clinical studies in China most commonly use CLSI. All isolates in the present study were susceptible to amoxicillin–clavulanic, ceftazidime, and ciprofloxacin according to CLSI, indicating that these antibiotics could be used for empirical treatment. The non-susceptibility rate to cefuroxime showed a significant difference according to different judgement criteria, being 13.5% according to CLSI and EUCAST, but 96.0% according to BSAC. This is a source of confusion for clinicians. Previous reports documented high susceptibility rates of M. catarrhalis isolates to third- and fourth-generation cephalosporins (such as ceftriaxone and ceftazidime) and amoxicillin–clavulanic, at nearly 100% [9, 11–14].
Isolates in the present study showed high resistance to erythromycin. Previous studies reported that 23S rRNA mutations A2330T and A2058T are major causes of resistance to macrolide antibiotics such as erythromycin [15–17]. Because the resistance of pathogens isolated from the respiratory tract to macrolide antibiotics is a serious concern in China, it is important to standardize the use of this antibiotic to help control and reduce the spread of resistance.
The β-lactamase positive rate in our study was high, at 99.4% (177/178 cases), which is in accordance with other recent findings (96.5%~ 100%) in China [14, 18, 19]. According to EUCAST, M. catarrhalis isolates producing β-lactamase should be reported as resistant to penicillins and aminopenicillins without inhibitors. However, we showed a resistance rate to ampicillin of 74.2% (Zhongjiang County, 81.8%; Youyang County, 68.3%) according to BSAC, suggesting that there is a discrepancy between β-lactamase production and resistance rates. We advise medical workers to pay attention to the high resistance rate and possible discrepancies in rates during their routine work.
Conclusions
In summary, 99% of M. catarrhalis strains of the present study were shown to produce β-lactamase. The isolates showed high susceptibility to third- and fourth-generation cephalosporins and amoxicillin–clavulanic, and poor susceptibility to ampicillin and erythromycin. However, some notable discrepancies were observed between susceptibility rates obtained with different antibiotic resistance judgemnet criteria for M. catarrhalis isolates. Therefore, additional long-term surveys are required to monitor the antimicrobial resistance of this important human pathogen with the aim of standardizing criterion.
Acknowledgments
We thank Sarah Williams, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn), for editing the English text of a draft of this manuscript.
Much thanks for the opportunity to show our research results from the 10th World Congress of the World Society for Pediatric Infectious Diseases (WSPID 2017) [20], and the 11th International Symposium on Antimicrobial Agents and Resistance and the 3rd International Interscience Conference on Infection and Chemotheropy (ISAAR & ICIC 2017) [21].
Funding
This study was financially supported by the Research Funds of Profession Quota Budget from the Beijing Municipal Science and Technology Commission (2016-bjsekyjs-3) and the medical research project of Chongqing Health and Family Planning Commission (No.2016ZDX041).
The funding body had no role in the design of the study or collection, analysis, and interpretation of data or in writing the manuscript.
Availability of data and materials
The data supporting the conclusion of this article are included within the article, and all of the datasets used and/or analyzed during the current study are available from the corresponding author.
Abbreviations
- BSAC
British Society for Antimicrobial Chemotherapy
- CAP
Community-acquired pneumonia
- CLSI
Clinical and Laboratory Standards Institute
- EUCAST
European Committee on Antimicrobial Susceptibility Testing
- MIC
Minimum inhibitory concentration
Authors’ contributions
WS, DW, CC, and KY designed the study. LY, WG, PT, and XC collected the isolates and performed the antimicrobial susceptibility test. WS, DW, CC, and KY collected the data, analyzed them, interpreted the results, and drafted the manuscript. All authors reviewed and revised the manuscript and approved the final version.
Ethics approval and consent to participate
A parent and/or legal guardian of each participant signed a written informed consent document before enrollment and before any study procedure was performed. This study was approved by the Ethics Committee of the two hospitals (Ethics Committee of People’s Hospital of Zhongjiang County, and Ethics Committee of People’s Hospital of Chongqing Youyang County). No ethical problems were encountered in this study.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Footnotes
Wei Shi, Denian Wen and Changhui Chen contributed equally to this work.
Contributor Information
Wei Shi, Email: shiwei613115@126.com.
Denian Wen, Email: 1142429940@qq.com.
Changhui Chen, Email: cchwl1972@sohu.com.
Lin Yuan, Email: Yuanyuan808yuan@sina.com.
Wei Gao, Email: weigw2000@sina.com.
Ping Tang, Email: 731829145@sina.com.
Xiaoping Cheng, Email: yywt2004@163.com.
Kaihu Yao, Phone: +8601013370110178, Phone: +8601059616981, Email: Jiuhu2655@sina.com.
References
- 1.Aebi C. Moraxella catarrhalis-pathogen or commensal? Adv Exp Med Biol. 2011;697:107–116. doi: 10.1007/978-1-4419-7185-2_9. [DOI] [PubMed] [Google Scholar]
- 2.Ren D, Pichichero ME. Vaccine targets against Moraxella catarrhalis. Expert Opin Ther Targets. 2016;20(1):19–33. doi: 10.1517/14728222.2015.1081686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Wang H, Chen M, Xu Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the community-acquired respiratory tract infection pathogen surveillance (CARTIPS) STUDY, 2009-2010. Int J Antimicrob Agents. 2011;38(5):376–383. doi: 10.1016/j.ijantimicag.2011.06.015. [DOI] [PubMed] [Google Scholar]
- 4.Malmvall BE, Brorsson JE, Johnsson J. In vitro sensitivity to penicillin V and beta-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother. 1977;3(4):374–375. doi: 10.1093/jac/3.4.374. [DOI] [PubMed] [Google Scholar]
- 5.Fung CP, Powell M, Seymour A, Yuan M, Williams JD. The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in 1991. J Antimicrob Chemother. 1992;30(1):47–55. doi: 10.1093/jac/30.1.47. [DOI] [PubMed] [Google Scholar]
- 6.Doern GV, Jones RN, Pfaller MA, Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial suscepitibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997) Antimicrob Agents Chemother. 1999;43(2):385–389. doi: 10.1128/aac.43.2.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Pingault NM, Bowman JM, Lehmann D, Riley TV. Antimicrobial susceptibility of Moraxella catarrhalis isolated from children in Kalgoorlie-boulder, Western Australia. Pathology. 2010;42(3):273–279. doi: 10.3109/00313021003631270. [DOI] [PubMed] [Google Scholar]
- 8.Clinical and Laboratory Standards Institute (CLSI) Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious Bacteria; approved guideline. M45-A. 2014;26(19):28–29. [Google Scholar]
- 9.Andrews JM. BSAC working party on susceptibility testing. BSAC standardized disc susceptibility testing method (version 8) J Antimicrob Chemother. 2009;64(3):454–489. doi: 10.1093/jac/dkp244. [DOI] [PubMed] [Google Scholar]
- 10.Morrissey I, Maher K, Williams L, Shackcloth J, Felmingham D, Reynolds R et al. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community -acquired respiratory tract infections in the UK and Ireland, 1999–2007 [J]. J Antimicrob Chemother, 2008, 62 Suppl 2:ii97–i103. [DOI] [PubMed]
- 11.Bandet T, Whitehead S, Blondel-Hill E, Wagner K, Cheeptham N. Susceptibility of clinical Moraxella catarrhalis isolates in British Columbia to six empirically prescribed antibiotic agents. Can J Infect Dis Med Microbiol. 2014;25(3):155–158. doi: 10.1155/2014/370964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Abdullah FE, Ahuja KR, Kumar H. Prevalence and emerging resistance of Moraxella catarrhalis in lower respiratory tract infections in Karachi. J Pak Med Assoc. 2013;63(11):1342–1344. [PubMed] [Google Scholar]
- 13.Che DD, Zhang H, Lu Q, Zhang YC, Lu M, Li WH. Study on Moraxella catarrhalis resistance and bro genotyping in children with acute lower respiratory tract infection. Chin J Pediatr. 2009;24(8):606–609. [Google Scholar]
- 14.Luo YP. Analysis of pathogenic bacteria distribution and drug resistance in specimens of pediatric respiratory infection. J Modern Clin Med. 2016;42(1):52–54. [Google Scholar]
- 15.Liu Y, Xu H, Xu Z, Kudinha T, Fan X, Xiao M, Kong F, Sun H, Xu Y. High-level macrolide-resistant Moraxella catarrhalis and development of an allele-specific PCR assay for detection of 23S rRNA gene A2330 mutation: a three-year study at a Chinese tertiary hospital. Microb Drug Resist. 2015;21(5):507–511. doi: 10.1089/mdr.2014.0217. [DOI] [PubMed] [Google Scholar]
- 16.Iwata S, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K. Genetic analysis of a pediatric clinical isolate of Moraxella catarrhalis with resistance to macrolides andquinolones. J Infect Chemother. 2015;21(4):308–311. doi: 10.1016/j.jiac.2014.11.002. [DOI] [PubMed] [Google Scholar]
- 17.Kasai A, Ogihara S, Yamada K, Tanimichi Y, Nishiyama H, Saito R. Prevalence and olecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011. J Med Microbiol. 2015;64(7):708–713. doi: 10.1099/jmm.0.000076. [DOI] [PubMed] [Google Scholar]
- 18.Wang PJ, Xie CB, Wu YL. Antimicrobial resistance and BRO genotyping of Moraxella catarrhalis isolates from respiratory tract in children. J Clin Pediatr. 2013;31(8):719–722. [Google Scholar]
- 19.Lin AX, Tan N, Yang XH, Li LL. The specimen distribution and antibiotic susceptibility analysis of 997 Moraxella catarrhalis isolates. Int J Lab Med. 2016;37(3):376–377. [Google Scholar]
- 20.Yao K, Shi W. β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China. WSPID 2017; WSPD7–0415. https://wspid2017.kenes.com/Documents/WSPID17_-all%20abstracts.pdf. Accessed 2 Dec 2017. [DOI] [PMC free article] [PubMed]
- 21.Shi W, Yao K. β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China. ISAAR& ICIC 2017; P1-GN03. https://www.sciencedirect.com/science/article/pii/S0924857917303424?via%3Dihub. Int J Antimicrob Agents 50 S1 (2017) S94. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data supporting the conclusion of this article are included within the article, and all of the datasets used and/or analyzed during the current study are available from the corresponding author.